ISSCR

Listen to our innovation showcase, view our posters or pop by our booth!

Come and visit our team at our stand #222 to discuss how bit.bio offers partnering opportunities that affords access to the most relevant parental human cell types and corresponding disease models. These models are physiologically relevant and highly characterised, offering predictive, in vitro, human cells for early drug discovery, phenotypic screening, and high-content imaging applications.

Innovation Showcase:

We will also be hosting a 60 minute innovation showcase on Thursday 15th June between 12:00pm – 1:00 pm. Come and join us for coffee and cookies and listen to our talk on 'Industrialising Cellular Reprogramming: Leveraging opti-ox™ Technology to Manufacture Human Cells with Unprecedented Consistency'.

Transcription factor-mediated cellular reprogramming has emerged as a groundbreaking paradigm in developmental biology, challenging traditional theories and opening new avenues for further scientific innovations. 

Prof Wernig will discuss his pioneering work on cellular reprogramming, which opened up a new paradigm for cell identity, in which cellular states are driven by transcriptional events. His laboratory developed the first across germ layer reprogramming protocols highlighting the potential generalisability of this concept. His group demonstrated how transcription factor combinations are able to dictate cellular states and sub-cell identities. Based on this new paradigm, he developed new cellular models for translational research and outlined how reprogrammed cells could be used for therapeutic applications. 

Despite the benefits of cellular reprogramming, several challenges associated with conventional vector-based methods of transgene expression impact the efficiency, consistency and purity of the resulting cell populations, all of which need to be addressed for its potential to be truly realised in regenerative medicine. 
 
As Dr Kotter will outline, many of these challenges can be addressed by expressing reprogramming cassettes via genomic safe harbour (GSH) sites. GSH-mediated optimised inducible over-expression (opti-ox) enables highly controlled, consistent and scalable manufacturing of human iPSC-derived cells. Further, he will discuss how bit.bio has generalised this paradigm to generate cells from all three germ layers. 

The integration of opti-ox technology ensures increased precision and inducible control of transcription factor expression, setting a new standard for consistency in cell manufacturing. This breakthrough enables the manufacture of trillions of human cells with unprecedented consistency offering the potential to transform the field of regenerative medicine and accelerate advancements in cell-based therapies. 

Poster Presentations:

Dario Pacitti | Senior Scientist
 #1506430 
"Optimised and scalable reprogramming of human iPSCs to generate nociceptor sensory neurons for the study of pain mechanisms and neuropoathies" 

Malathi Raman Srivastava​ | Snr Product Manager
#1509289 
"Rapid and consistent generation of functional microglia from reprogrammed hiPSCs to study mechanisms in neurodegeneration and neuroinflammation"

Gianmarco Mastrogiovanni​ | Team Leader
#1509019
"Generation of highly pure, consistent and functional inhibitory gabaergic neurons from human iPSCs using opti-ox technology"

Will Bernard​ | Director, Cell Type Development
#1508936 
"Modelling neurodegeneration using a human isogenic system: A next generation approach to study frontotemporal dementia and amyotrophic lateral sclerorsis"

Listen to our welcome remarks in our sponsored track “Modeling Development and Disease" and see how bit.bio can support drug discovery. We are also delighted to be a friend of the early career scientist social night to support upcoming stars of the future.